Managing ROS1 fusion-positive NSCLC in Europe and the USA

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 27 / Springer Healthcare

Managing ROS1 fusion-positive NSCLC in Europe and the USA

Oncology Non-Small Cell Lung Cancer

Description

Luis Paz-Ares leads Jaime Schneider and Benjamin Besse in a discussion on the management of patients with ROS1 fusion-positive NSCLC in 2022.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.